Introduction
Fatigue is the only symptom reported by the majority of cancer patients in all diagnostic groups (Stone, Richardson, Ream, Smith, Kerr, & Kearney, 2000) . It can influence quality of life, adherence to medical therapy, and activities of daily living (Ferrell, Grant, Dean, Funk, & Ly, 1996) . Unfortunately, interventions to combat fatigue are not routinely offered to help patients cope with its impact, despite the fact that there is a growing body of evidence to support the practice (NCCN, 2007) .
Clinicians cite busy clinical settings, heavy patient caseloads, and lack of easily applied instruments to identify patients who are experiencing fatigue, as reasons why fatigue is not routinely acknowledged during a clinical consultation. In a patient and chart audit with 46 cancer patients attending our clinic, fatigue was documented in 32% of the patient records while 89% of the patients themselves reported fatigue (Fitch, Mings, & Lee, 2008) . Additionally, fatigue was cited as a primary patient concern by patients within lung (Fitch & Steele, 2010) , advanced disease (Fitch, 2010) , and gynecologic (Steele & Fitch, 2008) populations.
Responding to the need for an easily administered and scored instrument to measure fatigue, we designed a new tool for rapid screening of fatigue in busy clinical environments, the Fatigue Pictogram. With a psychometrically sound instrument, patients can be triaged efficiently for concerns about fatigue. The instrument can trigger health care professionals to pay attention to fatigue and monitor the symptom over time. An initial psychometric evaluation with lung cancer patients showed the tool was reliable and valid for that patient group (Fitch, Bunston, Bakker, Mings, & Sevean, 2011) . This article presents new psychometric evidence regarding the Fatigue Pictogram and its performance in a wider population of cancer patients receiving chemotherapy (i.e., across several diagnostic sites).
Background
Although the meaning of fatigue is intuitively clear, as an empirical phenomenon, fatigue has many different meanings. Fatigue is seen as subjective and multidimensional (Winningham, Nail, Burke, Brophy, Cimprich, Jone, et al., 1994) , having different modes of expression (Smets, Garssen, Cull, & de Haes, 1996) , existing along a continuum, and involving energy depletion (Irvine, Vincent, Grayson, Bubela, & Thompson, 1994) . In cancer circles, fatigue is frequently defined as a condition characterized by subjective feelings of tiredness, loss of strength, and endurance or energy that varies in degree, frequency, and duration with different modes of expression (e.g., physical, cognitive, emotional and motivational) (Olson, Tom, Hewitt, Whittingham, Buchanan, & Ganton, 2002) .
The prevalence of fatigue has been well documented with estimates ranging from 70% to 100% (Donovan, Jacobson, Andrykowski, Winters, Balucci, Malik, et al., 2004; Ancoli-Israel, Liu, Marler, Parker, Jones, Sadler, et al., 2006) during chemotherapy and from 80% to 100% during radiotherapy (Berglund, Bolund, Fornander, Rutqvist, & Sjoden, 1991) . The majority of patients with advanced disease experience fatigue (Olson, Krawchuk, & Qudussi, 2007) . It is seven times more prevalent in the cancer population than in the general population (Cella, Lai, Chang, Peterman, & Slavin, 2002) and is qualitatively different. For cancer patients, fatigue is rarely relieved by rest or sleep (Olson, Krawchuk, & Qudussi, 2007) .
Cancer-related fatigue can be mild to moderate or severe. It is not directly related to type of cancer, cancer stage, size of tumour, number of nodes or the presence or site of metastases (Servaes, Verhagen, & Bleijenberg, 2002) , but tends to increase over the course of treatment (Irvine et al., 1994) . Although for most it dissipates after treatment, fatigue may persist for several years (Berglund et al., 1991) .
Fatigue becomes significant for individuals when it adversely affects an individual's quality of life (Truong, Berthelet, Lee, Patersen, Lim, Gaul, et al., 2006) . In a convenience sample of 910 men and women with cancer, fatigue was observed to have an impact on all four dimensions of quality of life: physical, psychological, social, and spiritual (Ferrell, Grant, Dean, Funk, & Ly, 1996) .
Clinical assessment of fatigue facilitates the application of appropriate interventions. Changes in the patients' drug regimen, reversal of anemia or metabolic abnormalities, or treatment of sleep disorders or depression are potential avenues for intervention (Portenoy & Itri, 1999) . The nonpharmacologic approaches are also showing benefits for some patients. These include walking or exercise programs (Windsor, Nicole, & Poller, 2004 ) educating patients about fatigue (Yates, Aranda, Hargraves, Mirolo, Clavarino, McLachlan, et al., 2005) and individual counselling by professionals (Mitchell, Beck, Hood, Moore, & Tanner, 2007) .
Over the years, several instruments have been developed to measure fatigue in cancer populations from the patient's perspective across its several dimensions (Smets et. al., 1996; Cella, 1997; Piper, 1990) . However, these tools were originally developed as research
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Margaret I. Fitch, RN, PhD, Odette Cancer Centre, 2075 Bayview Avenue, T-wing, Toronto, ON M4N 3M5. Telephone: 416-480-5891; Fax: 416-480-7806; Email: marg.fitch@sunnybrook.ca Terry Bunston, MSW, PhD (deceased) Deborah Mings, RN, MHSc, GNC(C) , IIWCC, Burlington, ext. 46877; Email: dmings@bellnet.ca doi:10.5737/1181912x2214246 instruments and not screening tools. Their length and complexity preclude easy administration and interpretation within a busy clinical setting. In response to the need for a brief tool to measure fatigue, we designed the Fatigue Pictogram. It was developed to measure the two dimensions of fatigue most frequently described by patients (i.e., how tired they feel and how much they are not able to do within their daily activities). It was meant to be used as a screening or triage device, identifying patients who were experiencing difficulties with fatigue and setting the stage for deeper assessment and intervention. Given the promising results of the initial psychometric evaluation in a group of lung cancer patients, we wanted to assess the tool's performance in a different and more inclusive population.
Purpose
This paper will report on a psychometric evaluation of a newly developed fatigue screening instrument conducted in a mixed group of cancer patients receiving chemotherapy in an outpatient setting. Assessing the psychometric properties and performance of a new measurement device across populations is important if appropriate clinical decisions are to be made based on the tool. In this study, reliability and validity will be reported, as well as the performance in correctly categorizing or identifying patients with clinically significant fatigue. Reliability is defined as the extent to which an instrument yields the same results (consistency) on repeated measures (Nunnally & Bernstein, 1994) . Both consistency over time (testretest) and over method (telephone and in person) were considered relevant. Validity refers to whether an instrument accurately measures what it is supposed to measure (Nunnally & Bernstein, 1994) . Evaluation against standard validated fatigue and quality-of-life measures were undertaken to determine concurrent and construct validity.
Methods
The study protocol was submitted and approved by the ethics review board of the cancer centre. Patient accrual occurred in the reception area of the ambulatory clinic while patients waited for their chemotherapy treatment appointments. The study coordinator assessed patients for eligibility together with the clinic nurse according to the following criteria: a definitive diagnosis of cancer, 18 years of age or older, able to speak English, and not experiencing current mental illness or high emotional distress. The coordinator approached eligible patients, explained the study requirements, and invited their participation. Those who consented to participate completed an informed consent document and began the first round of data collection while in the clinic setting. A package of data collection materials was provided for the participating individuals to take home with them and use in the subsequent interactions with the study coordinator over the telephone.
Participation: Individuals who participated in this study completed the data collection instruments on three occasions. The patients completed the instruments in the waiting area of the chemotherapy suite on the first occasion (Time 1) during a face-to-face interaction with the study coordinator. The rest of the data collection was completed over the telephone according to the following schedule: time 2 occurred 24 hours after time 1 and time 3 occurred 24 hours after time 2. This schedule allowed for the determination of reliability between two methods (face-to-face and telephone), as well as short-term test-retest (over the telephone during 24 hours). We wanted to determine if the reliability coefficients for the Fatigue Pictogram would be similar in this population of mixed cancer patients to those we observed in an earlier study with lung cancer patients (Fitch et al., 2011) . Additionally, we wanted to add to the evidence regarding validity of the new instrument by comparing scores from the Fatigue Pictogram with those of validated measures for fatigue (MFI) and quality of life (FACT-an).
Data collection instrumentation:
The data collection tools for this study included a demographic data sheet, the newly developed Fatigue Pictogram, the Multi-dimensional Fatigue Inventory (MFI) (Smets et al., 1996) and the FACT-an (Cella, 1997) as the quality-oflife instrument. The Eastern Co-operative Oncology Group (ECOG) performance status scale and hemoglobin levels were also gathered (Zubrod, Schneiderman, Frei, Brindley, Gold, Snider, et al., 1960) .
The Fatigue Pictogram (see Figure 1 ) was developed as an easily administered and scored tool for measuring fatigue in a clinical setting. The notion of incorporating pictures meant that patients with limited English language and reading capacity could still utilize the tool. There are two questions or items measuring the dimensions patients talk most frequently about when describing their fatigue. Question 1 asks, "How tired have you felt over the last week?" and elicits responses on a five-point Likert scale ranging from "not at all' (scored as 0) to "very tired" (scored as 4). Question 2 asks, "How much does feeling tired prevent you from doing what you want to do?" Responses range from "I can do everything I normally do" to "I can do very little" and are scored from 0 to 4. Each response option is depicted in a picture with a generic figure together with an appropriate colour (See Figure 1) . Words are written under each of the pictures as well, but no numbers are evident to the patients completing the tool. The Fatigue Pictogram is formatted on a laminated card with one question on either side. The card can be carried easily in a uniform or lab coat pocket and shown to patients in the clinical setting. The response can be charted in the patient record in numerical form and easily tracked over time.
The Multidimensional Fatigue Inventory (MFI) (Smets et al., 1996) was developed for use with cancer patients. It is a 20-item instrument that measures five dimensions of fatigue: general, physical, mental, reduced motivation, and reduced activity. A factor analysis supported the five dimensions and, in cancer populations, Cronbach's alphas for the subscales ranged from 0.77 to 0.86. The instrument has been shown to have construct and convergent validity.
The FACT-an is a 48-item instrument that elicits an assessment of functional impact of cancer, symptoms, and concerns of patients with anemia. Twenty-eight items measure functional impact, 13 assess fatigue, and the remaining seven focus on anemia-related concerns. Both stability (test-retest) and internal consistency of the scale are good when tested in cancer patients (Yellen, Cella, Webster, Blendowski, & Kaplan, 1997) . In particular, the anemia items revealed strong association to patient rated performance and hemoglobin levels.
Statistical analysis: For the analysis, the raw data were summarized and descriptive statistics were calculated. Reliability was assessed using the Weighted Kappa Statistic and the Spearman Co-relation coefficient for the Fatigue Pictogram and using Pearson Product Moment Formula for the MFI and FACT-an. Reliability regarding equivalence of method was tested using Time 1 and Time 2 data while the test-retest reliability was determined using the Time 2 and Time 3 data. Concurrent validity was assessed by determining the extent to which the same participants were classified as fatigued by the Fatigue Pictogram scores and the MFI scores on the two relevant subscales (general, reduced activity).
Construct validity was assessed by dividing the sample according to hemoglobin levels (i.e., < 110, 110-119, > 119) and calculating descriptive statistics for each group across the study variables. It was anticipated that fatigue would be higher for those individuals with low hemoglobin levels.
Results

Selected sample characteristics
A total of 220 cancer patients receiving chemotherapy participated in all three steps of data collection. Approximately two-thirds (68.2%) were women and one-third (31.8%) were men. Sixty-seven per cent were married. The average age at the time of diagnosis was 59.2 (SD = 12.8) with a range of 24 to 89 years. Forty per cent had completed college or university while 15.9% had less than high school education. The participants represented an array of disease sites: breast (39.1%), GI (13.2%), GU (12.7%), Gyne (7.7%), hematology (6.4%), Lung (5.9%), melanoma/skin (5.4%), head & neck (5.1%) and other (5.9%).
Distribution of performance status, fatigue and quality of life scores
The ECOG scores showed a range in performance status for the sample on all three occasions (see Table 1 ) from normal activity to being in bed more than 50% of the time. By Time 3, a slightly larger proportion of individuals spent time in bed (24.5% to 31.9%). Responses to the Fatigue Pictogram questions also illustrated a range of responses with an increase in the proportion of individuals feeling tired (52.3% to 55.7%) and being unable to engage in activities (23.2% to 29.1%) from Time 1 to Time 3 (see Table 1 ). The total mean scores for the MFI increased slightly (71.7 to 72.9) from time 1 to Time 3, as did those of the FACT-an (23.4 to 24.0). However, none of the increases were significant (see Table 2 ).
Reliability
The reliability of the Fatigue Pictogram and of the two previously validated scales were determined for equivalence of method (face-to-face versus over the telephone) and test-retest (over the telephone within 24 hours). Table 3 Hemoglobin levels were available on the patient records for 168 participants at the time of entry into this study. When these data were used to divide this sample into normal (Hgb > 119), reduced (Hgb 119-110), and low (Hgb < 110) hemoglobin groupings, 29.2% of the participants had hemoglobin levels below normal and 7.7% were in the low category.
Across all variables, the group with normal hemoglobin levels had the best scores when compared to the other two groups (see Table  4 ). Responses to Question 1 of the Fatigue Pictogram showed 29.1% of the participants in the normal hemoglobin group as moderately or Unable to get out of bed --0.5 Table 2 . Mean scores for MFI and FACT-an in a mixed group of cancer patients receiving chemotherapy on three occasions extremely fatigued in contrast to 33.6% in the reduced group and 53.8% in the low group. The total MFI score was 73.9 (± 22.8) for the normal hemoglobin group in contrast to 79.8 (± 19.0) for the group with low hemoglobin. However, this observation was not statistically significant. However, there was interesting variation in the scores within each of these groups. For example, 8.2% the group with normal hemoglobin levels indicated they were extremely fatigued and not able to do very much; yet, 23.1% of the group with low hemoglobin levels reported being able to do all or almost all activities and no one reported being extremely fatigued.
Discussion
The Fatigue Pictogram was designed to be an easily administered and scored measurement device for use in a busy clinical setting. It was designed to help clinicians quickly and reliably triage which cancer patients were experiencing fatigue and required further assessment and intervention. An initial psychometric evaluation was undertaken to assess reliability and validity of this new screening tool in a group of lung cancer patients. This study offered a second evaluation of the psychometric properties in a mixed group of cancer patients receiving chemotherapy. The results in this study were consistent with those of the initial psychometric evaluation in lung cancer patients (Fitch et al., 2011) .
Patients had no difficulty indicating a response to the Fatigue Pictogram, even with limited English. The pictures and the colors facilitated response. Clearly, this design feature is a real benefit of the Fatigue Pictogram. The scores were calculated easily and were readily available to the clinical team as a basis for conversations about fatigue with the patient. There was a range in responses for each Fatigue Pictogram question. This indicated the tool was capable of capturing the variation in fatigue perspectives one would expect to observe in patients receiving chemotherapy. That fatigue was both present and existed to varying degrees in the study sample as confirmed by the ECOG scores.
The reliability coefficients indicated good consistency between method of administration (face-to-face and over the telephone) and test-retest over the 24-hour period (same method -over the telephone). As was expected, the strongest agreement was observed in the case of the same method (over the telephone) over a short time period (24 hours), the scenario with the least likelihood of change.
The validity results were consistent with the anticipated or hypothesized directions. Given the Pictogram was designed to measure the dimensions of physical tiredness and activity levels, the scores for the pictogram questions corresponded strongly with the physical and activity subscales of the Multidimensional Fatigue Inventory. Specifically, the responses for both Question 1 and Question 2 of the Fatigue Pictogram matched the total score patterns on the Multidimensional Fatigue Inventory. Patients reported high fatigue consistently on both measures. These results support the notion that the Fatigue Pictogram measures the physical dimension of fatigue and the related activity levels rather than other aspects of fatigue (i.e., mental) and is able to classify individuals accurately as fatigued or experiencing reduced activity because of fatigue.
Construct validity can be claimed for the Fatigue Pictogram based on the performance related to the theoretical notion or hypothesis that individuals with normal hemoglobin levels would have lower fatigue levels than those with reduced or low hemoglobin levels. The patterns across the range of variables for the three groups categorized by hemoglobin levels supported this notion, although the differences were not statistically significant. There were relatively wide variations in the perspectives reported by the participants about their feelings of tiredness and what they were able to do within each group, indicative of the subjective nature of fatigue that may not be entirely a function of hemoglobin levels (Servaes et al., 2002) . Additionally, if patients had had low hemoglobin levels for a lengthy period of time, they may have adapted and found ways to perform their activities.
Implications
Psychometric evaluation of a new measurement device is an important aspect of its development. Taking the time to ensure both reliability and validity provides assurance about the instrument's performance and instills confidence about making clinical decisions based on the instrument scores. Using standardized measurement devices helps in documentation and monitoring of symptoms or side effects over time. Tools that facilitate standardized numerical documentation facilitate consistent recording in electronic patient records.
The results support the use of the new device as an easily administered measurement device for quickly identifying if patients are experiencing fatigue. The Fatigue Pictogram can be used with confidence as a screening device to classify individuals who are experiencing fatigue and could benefit with further assessment and potential intervention. The tool may be utilized during face-to-face interactions, as well as over the telephone. Given the importance patients attribute to fatigue and the virtually universal experience of this symptom, it is imperative that oncology nurses incorporate screening, assessment and intervention regarding fatigue into their practice. However, introducing a tool such as the Fatigue Pictogram into routine practice will require concerted planning and careful implementation. Introduction of the screening tool will drive a change in current practice and will necessitate astute evaluation of its impact. A practice change will be required regarding systematic screening, assessment, intervention, and documentation for fatigue given the present gaps in clinical practice regarding this side effect. Although the evidence regarding fatigue intervention is growing, practitioner behaviour regarding its uptake and utilization necessitates attention to programmatic approaches and intentional education strategies (NCCN, 2007) .
Additional psychometric evaluation of the tool would be beneficial. Attention needs to be given to treatment stage and administration in this future work. Finally, given the ease with which this tool can be used, having patients utilize the instrument as a monitoring device and part of their own self-management program would be of interest.
